VEGF-Inhibitor Hypertension: Managing Pressure Without Interrupting Cancer Therapy

Baseline and cadence

Record a reliable baseline before therapy starts, including home readings where possible, and address any pre-existing uncontrolled hypertension first. Monitor at least weekly through the first cycle and then regularly through treatment, with home monitoring and a written log giving far better data than clinic readings alone.

Teach correct technique explicitly. Much of what looks like refractory hypertension in this setting is cuff size, arm position, or timing relative to dose.

Agent selection

Renin-angiotensin system blockade and dihydropyridine calcium channel blockers are the usual first choices, with the caveat that non-dihydropyridine agents interact with several oncology drugs through hepatic metabolism and are generally avoided.

Renal function, proteinuria, and concurrent nephrotoxic therapy influence the choice, so check renal indices and urine protein alongside pressure rather than in isolation.

Escalation on a schedule

Set a target and a timeline before starting: if pressure is above target at the next check, increase or add rather than observe. Reassess within one to two weeks of every change. A short, named escalation pathway agreed between oncology and primary care prevents the drift that ends in a held dose.

Severe hypertension, hypertensive symptoms, or any suggestion of posterior reversible encephalopathy require urgent assessment and immediate oncology contact.

Coordination

Document who owns the pressure between cycles, how the oncology team is contacted when control fails, and what threshold triggers a conversation about dose. Dose modification is an oncology decision, and it should follow a documented antihypertensive escalation rather than precede it.